AMP Capital Investors’s Myriad Genetics MYGN Stock Holding History

AMP Capital Investors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-6,300	Closed	-$235K	–	1221
2016 Q1	$235K	Buy	+6,300	New	+$237K	﹤0.01%	1079
2015 Q3	–	Sell	-10,700	Closed	-$357K	–	1223
2015 Q2	$357K	Buy	+10,700	New	+$364K	﹤0.01%	1023
2014 Q4	–	Sell	-52,861	Closed	-$2.06M	–	1160
2014 Q3	$2.06M	Buy	52,861 +4,900	+10%	+$183K	0.01%	733
2014 Q2	$1.88M	Buy	47,961 +6,700	+16%	+$249K	0.01%	759
2014 Q1	$1.36M	Sell	41,261 -44,839	-52%	-$1.39M	0.01%	819
2013 Q4	$1.79M	Buy	+86,100	New	+$2.18M	0.01%	749

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

AMP Capital Investors's MYGN Position: Q2 2016 in Review

AMP Capital Investors sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 6,300 shares — an estimated $235K sold.

AMP Capital Investors first reported a position in MYGN in Q4 2013 and held it in 6 quarters. The position peaked at $2.06M in Q3 2014. 252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

AMP Capital Investors reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
AMP Capital Investors sold 6,300 Myriad Genetics shares in Q2 2016, an estimated $235K.
AMP Capital Investors first reported a position in Myriad Genetics in Q4 2013 and held it in 6 quarters.
AMP Capital Investors's Myriad Genetics position peaked at $2.06M in Q3 2014.
252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on AMP Capital Investors's 13F filing for Q2 2016, filed 15 Aug 2016.